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Abstract
Purpose:  To determinate glycosylation of selected acute-
phase  glycoproteins  (AGP,  ACT,  CP)  and  serum  concen-
tration of this proteins in Systemic Lupus Erythematosus 
(SLE) patients.
Patients and methods:  The study was carried out on 35 
patients  with  active  SLE  and  15  healthy  volunteers.  The 
immunological measurements were performed at first day 
of  hospitalisation,  before  receiving  treatment.  The  con-
centration of CRP, AGP, ACT and CP were evaluated by 
electroimmunoassay  using  anti-AGP,  anti-ACT,  anti-CP 
antibodies. CRP levels were determined by radial immuno-
diffusion with anti-CRP antibodies. The microheterogeneity 
of the acute phase proteins was assessed by agarose affinity 
electrophoresis using Con A as a ligand, as was described by 
Bøg-Hansen. 
Results:  Between  SLE  patients  and  control  group  sta-
tistically significant differences (p<0.01) were observed in 
serum concentration of all investigated parameters. There 
were no significant differences in serum acute-phase pro-
teins levels with regards to patient’s age, sex and disease 
activity. The reactivity coefficients: AGP-RC, ACT-RC, CP-
RC in SLE patients were similar to the healthy group. The 
precipitate curves were similar in both groups. The main dif-
ference was in the area of the precipitant, which was bigger 
in the SLE patients.
Conclusions:  Configuration  of  analysis  serum  concen-
tration and heterogeneity of acute-phase proteins is one of 
important diagnostic tests in SLE.
Key words:   Systemic Lupus Erythematosus, acute-phase 
proteins, heterogeneity, glycosylation.
Abbreviations: SLE – Systemic Lupus Erythemetosus, APP 
–  acute-phase  proteins,  AGP  –  1-acid  glycoproteins,  ACT 
–  antichymotripsin,  CP  –  ceruloplasmin,  CRP  –  C-reactive 
protein, RC – reactivity coefficient, Con A – concanavalin A, 
IL-interleukin.
Introduction
The  concentration  and  microheterogeneity  of  acute-phase 
proteins (APP) differs in acute and chronic types of inflammation 
[1,2]. The qualitative changes of some acute-phase glycoproteins 
are referred as a major microheterogeneity. Affinity electropho-
resis with a lectin, concanavalin A (Con A) as a ligand has been 
successfully used to determine acute-phase glycoproteins micro-
heterogeneity.  The  concentration  and  microheterogeneity  of 
acute-phase proteins can be used in early diagnosis, management 
and prognosis of chronic inflammatory stages.
Systemic Lupus Erythematosus (SLE) is a chronic autoim-
munological inflammation and is the most clinically and sero-
logically diverse of the autoimmune connective tissue diseases; it 
may affects any organ of the body and displays a broad spectrum 
of clinical and immunological manifestations. In other chronic 
inflammatory disease, like in rheumatoid arthritis, ancylosing 
spondylitis, polymyalgia rheumatica and Crohn’s disease a sig-
nificantly decreased proportion of acute phase proteins reacting 
with Con A were observed. 
In  the  present  study,  we  evaluated  the  determination  of 
concentration and microheterogeneity of  1-acid glycoprotein 
(AGP), antichymtripsin (ACT), ceruloplasmin (CP) and C-reac-
tive protein (CRP) in early diagnosing of SLE. In order to get 
a better insight into acute-phase proteins network regulation 
in  Systemic  Lupus  Erythematosus,  we  analysed  levels  of  this 
proteins in the sera from 35 SLE patients. 
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Patients and methods
The  study  included  35  patients  with  active  SLE.  They 
had  been  hospitalised  in  The  Department  of  Rheumatology 
and  Internal  Diseases,  Medical  University  in  Białystok  from 
March 2001 to June 2003. All patients fulfilled The American 
Rheumatism  Association  revised  criteria  for  classification  of 
SLE [3]. The activity of the SLE was graded at the time of blood 
sampling, based on SLEDAI criteria [4]. The clinical profile of 
the patients is presented in the Tab. 1.
The  control  group  consisted  of  15  healthy  individuals 
(4  males, 11 females) with mean age of 42.3 years. There were 
no significant differences in age and sex between the patients 
and the controls.
Serum AGP, ACT, CP levels were measured by electroim-
munoassay  using  anti-AGP,  anti-ACT,  anti-CP  antibodies  [5]. 
CRP levels were determined by radial immunodiffusion with 
anti-CRP antibodies.  
The  microheterogeneity  of  the  acute-phase  proteins  was 
assessed  by  agarose  affinity  electrophoresis  using  Con  A  as 
a  ligand, as was described by Bøg-Hansen [6]. 50  M Con A was 
included in the first dimension gel. Electrophoresis was carried 
out for 60-70 minutes, at 20 V/cm. Two gel adjacent of the first 
dimension gel, one containing specific antibodies, and the other 
containing methyl-mannosid, were cast. Electrophoresis of sec-
ond dimension was carried out for 18 hours at 1.5 V/cm. The gel 
was dried and stained by Commasie brillant blue. This method 
reveals 4 microheterogeneous variants of AGP, ACT and CP. 
Variant 0 is nonreactive with ConA, variant 1st is slightly reac-
tive, variant 2nd – strongly reactive, 3rd – very strongly reactive, 
often precipitated in the first dimension. The area under the 
precipitate curves was determinated planimetry and the reactiv-
ity coefficient (RC) was calculated according to formula: 
All blood samples were collected from each patient before 
receiving treatment. Serum samples were stored at -80°C until 
assayed.
Statystical analysis
Data were presented as mean ± 1 SD or median (range), 
depending on distribution provided by Shapiro test. Data for 
concentration  in  serum  acute-phase  proteins  from  healthy 
individuals and patients with SLE were analysed using Student’s 
T-test.  In  the  case  of  skeweew  distribution  we  used  Mann-
Whitney’s  test.  Differences  between  group  were  regarded  as 
statistically significant at p<0.05.
Results
1-acid glycoprotein (AGP)
Serum levels of AGP in SLE patients with are shown in 
Tab.  2. AGP level in all patients with SLE were very high and 
were significantly higher than in healthy population (p<0.001). 
There were no significant differences in serum AGP levels with 
regards to patients age, sex and disease activity (p=0.52). The 
median reactivity coefficient (AGP-RC) was 1.29 (1.361-0.9760). 
AGP-RC was similar like in healthy individuals (p=0.321). The 
precipitate curves were similar in both groups. The main differ-
ence was in the area of the precipitant, which was bigger in the 
SLE patients (Fig. 1). 
Antichymotripsin (ACT)
The median levels of ACT in sera patients with SLE were 
669.0 ng/ml  (578.0-781.0  ng/ml)  and  were  significantly  higher 
compared with those in healthy individuals (p<0.001). There 
were no significant differences in serum AGP levels with regards 
to patients age, sex and disease activity (p=0.312).
The median reactivity coefficient (ACT-RC) in SLE patients 
was 3.98 (3.12-4.54) and was similar to ACT-RC in healthy group 
(p=0.123) (Fig. 2). The precipitate curves were similar in both 
groups. The main difference was in the area of the precipitant, 
which was bigger in the SLE patients. The picture was corre-
sponded to the AGP curves. 
Table 1. Characteristics of SLE patients 
Patients number  35
Sex (M:F) 3:32
Median age in years (range) 34.7 (21–50)
Median duration of disease in 
years (range)
6.9 (0.5-28.0) 
Clinical manifestations
Arthritis  13
Skin manifestation 20
Serositis 7
Fever 15
Positive antinuclear antibodies 
(ANA)
35
Haematological symptoms
Anaemia 25
Leukopenia 27
Thrombocytopenia 17
RC =
Sum of Con reactive variants
Sum of Con nonreactive variants
Table  2.  Medium  serum  levels  of  acute  phase  proteins  and 
medium reactivity coefficient in the SLE patients and healthy 
individuals 
SLE patients Healthy individuals
Median serum levels of 
AGP (ng/ml)
1234.0 (967.7-1615.7)* 623.7 (432.1-678.9)
RC-AGP 1.29 (0.976-1.361) 1.02 (0.876-1.298)
Median serum levels of 
ACT(ng/ml)
669.0 (578.0-781.0)* 221.6 (132.8-265.8)
RC- ACT 3.98 ( 3.12- 4.54) 4.25 (4.01-4.87)
Median serum levels of 
CP (ng/ml)
538.0 (481.0-589.0)* 267.7 (198.4-311.7)
RC- CP 1.298 (0.87-2.43) 1.4 (0.76-2.2)
Median serum levels of 
CRP (ng/ml)
21.7 (11.6-41.0)* 7.1 (2.9-13.5)
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Ceruloplasmin (CP)
The median levels of CP in sera patients with SLE were 
538.0 ng/ml (481.0-589.00 ng/ml). They were almost two times 
higher than in control group (p<0.001). There were no signifi-
cant differences in serum CP levels with regards to patients age, 
sex and disease activity (p=0.52).
The median reactivity coefficient (CP-RC) in SLE patients 
was 1.298 (0.87-2.43) and was similar to CP-RC in healthy group 
(p=0.123). The precipitate curves were similar in both groups. 
The main difference was in the area of the precipitant, which 
was bigger in the SLE patients. The picture was corresponded to 
the AGP and ACT curves. 
C-reactive protein
The median levels of CRP in sera patients with SLE were 
21.7 ng/ml (11.6-41.0 ng/ml). It was almost three times higher 
than in control group (p<0.001).
Discussion
Values  of  concentrations  of  acute-phase  protein  and 
decrease values of reactivity coefficient were previously found in 
chronic inflammatory processes. This parameter can be also use-
ful in diagnostic and management of SLE [7]. Changes observed 
in sera of SLE patients were similar to healthy individuals. Reac-
tivity coefficients of AGP, ACT and CP were normal, compared 
with results using sera control group. SLE activity did not alter 
the reactivity with Con A in sera SLE patients. Although con-
centrations of AGP, ACT, CP increase significantly. There was 
one exception – C-reactive protein. Generally levels of serum 
CRP were normal or only slightly higher than in control group. 
All these above featured changes are very typical for SLE. Some 
authors suggested that elevated levels of CRP might serve as 
a  marker for infection in SLE [8]. However, the usefulness of 
this measure has been controversy. 
Therefore, it seems likely that the reactivity of proteins with 
Con  A  depends  on  regulatory  mechanisms  of  inflammatory 
reaction than on the disease itself. Still unexplained is a lack 
of change and normal value of RC in active SLE. Unchanged 
glycosylation pattern in this disease may be explained by the very 
low stimulation of hepatic synthesis of proteins. The expression 
of this is very low C-reactive protein level. In the other hand lev-
els of AGP, ACT, CP were very high. This observation suggests 
that glycosylation is differently regulated than synthesis of the 
acute-phase proteins. The main role in the regulatory process 
has probably cytokines.
Baumann suggested that there are two main groups of cyto-
kines, which influence on synthesis and action of acute-phase 
proteins [10]. Type I cytokines (IL-1  ,   and TNF- ) stimulate 
the synthesis of such proteins like CRP, Serum Amyloid A, AGP. 
Macrophages and monocytes release these cytokines. They can 
also decrease synthesis of other proteins like CP, ACT. Type II 
cytokines  (interleukin-6,  interleukin-11,  leukemia  inhibitory 
factor) stimulate the second group of acute-phase proteins, like 
fibrinogen, ACT, CP [11]. 
Quantification of the serum IL-10 level showed increased 
levels in SLE and RA patients as compared to healthy controls. 
Serum IL-6 level was found to be elevated in SLE patients. IL-
10 has a potent immunosuppressive activity, IL-10 did not cor-
relate with APP either in SLE patients. However, the elevation 
of IL-10 serum levels in SLE and the correlation between IL-10 
and IL-6 in SLE may suggest that IL-10 may play a central role 
in regulation of synthesis acute-phase proteins [12].
It has been reported that the antibodies to modified CRP 
were present in some autoimmunological disease. These anti-
bodies represent a novel group of autoantibodies, first described 
in one patient with SLE and later in patients suffering from toxic 
oil syndrome (TOS). The occurrence of antibodies to CRP and 
to other acute-phase proteins in a larger group of patients with 
SLE and other autoimmune diseases were demonstrated [13]. 
Patients with SLE have a high incidence of antibodies to acute-
phase proteins, preferentially to CRP. 
 The diagnosis and management of SLE is still predominately 
based on clinical parameters. Nevertheless, specific laboratory 
diagnostic test may often be critically helpful. Configuration of 
analysis serum concentration and heterogeneity of acute-phase 
proteins is one of important diagnostic test in SLE.
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